Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 6/20 | 0.49 |
| ▸ | SELE | P16581 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | IGF2R | P11717 | 1/20 | 0.41 |
| ▸ | FGF1 | P05230 | 1/20 | 0.41 |
| ▸ | FGF2 | P09038 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7699917 | 0.93 | LGALS8 (0.42) | LGALS8SELEMEN1KMT2APTPN1 | |
| SCHEMBL7699916 | 0.93 | LGALS8 (0.42) | LGALS8SELEMEN1KMT2APTPN1 | |
| SCHEMBL17767393 | 0.92 | IGF2R (0.44) | LGALS8MEN1KMT2APTPN1IGF2R | |
| SCHEMBL8373863 | 0.90 | LGALS8 (0.48) | LGALS8SELEMEN1KMT2APTPN1 | |
| SCHEMBL19555100 | 0.86 | CD209 (0.46) | LGALS8SELEMEN1KMT2APTPN1 | |
| SCHEMBL17767386 | 0.85 | LGALS8 (0.46) | LGALS8TYR | |
| SCHEMBL8136408 | 0.85 | L3MBTL1 (0.46) | LGALS8L3MBTL1TYR | |
| SCHEMBL12290512 | 0.85 | L3MBTL1 (0.46) | LGALS8L3MBTL1TYR | |
| SCHEMBL8069003 | 0.85 | L3MBTL1 (0.46) | LGALS8L3MBTL1TYR | |
| SCHEMBL27654959 | 0.85 | L3MBTL1 (0.46) | LGALS8L3MBTL1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115501172-A | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-107249570-B | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-08-09 | — | — | CN | disclosed |
| US-20210386669-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2021-12-16 | — | — | US | disclosed |
| US-11065201-B2 | Gel formulations for local drug release | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2021-07-20 | — | — | US | disclosed |
| US-11058780-B2 | Palpable marker composition | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20190275174-A1 | PALPABLE MARKER COMPOSITION | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2019-09-12 | — | — | US | disclosed |
| EP-3458029-A1 | PALPABLE MARKER COMPOSITION | Technical University of Denmark (DK) | 2019-03-27 | — | — | EP | disclosed |
| CN-109475491-A | Palpable marker compositions | 丹麦技术大学 | 2019-03-15 | — | — | CN | disclosed |
| US-20180325819-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2018-11-15 | — | — | US | disclosed |
| WO-2017198858-A1 | PALPABLE MARKER COMPOSITION | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2017-11-23 | — | — | WO | disclosed |
| CN-107249570-A | Gel formulations for topical drug delivery | 丹麦技术大学 | 2017-10-13 | — | — | CN | disclosed |
| EP-3220887-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | Technical University of Denmark (DK) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079330-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079331-A1 | GEL FORMULATIONS FOR ENHANCING THE EFFECT OF RADIOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079332-A1 | GEL FORMULATIONS FOR IMPROVING IMMUNOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275174-A1 | PALPABLE MARKER COMPOSITION | TREH, LGALS8, PYGM | LGALS8 2/4885SELE 1828/4885MEN1 3511/4885 |
| US-11065201-B2 | Gel formulations for local drug release | TREH, GALE, SLC2A8 | LGALS8 19/4885SELE 1969/4885MEN1 4426/4885 |
| US-11058780-B2 | Palpable marker composition | TREH, LGALS8, PYGM | LGALS8 2/4885SELE 1828/4885MEN1 3511/4885 |
| US-20180325819-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | LGALS8 19/4885SELE 1969/4885MEN1 4426/4885 |
| US-20210386669-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | LGALS8 19/4885SELE 1969/4885MEN1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.